Group 1 - The Hong Kong Stock Connect Innovative Drug ETF (Southern, 159297) experienced a decline of 4.31% on October 30, with a trading volume of 242 million yuan [1] - The fund's shares increased by 148 million, bringing the total shares to 1.281 billion, with a total increase of 793 million shares over the past 20 trading days [1] - The latest net asset value of the fund is calculated to be 1.082 billion yuan [1] Group 2 - The performance benchmark for the Hong Kong Stock Connect Innovative Drug ETF is the Guozhen Hong Kong Stock Connect Innovative Drug Index (adjusted for valuation exchange rates) [1] - The fund is managed by Southern Fund Management Co., Ltd., with fund managers Zhang Qisi and Ye Zhenan [1] - Since its establishment on September 12, 2025, the fund has reported a return of -15.57%, with a return of -14.79% over the past month [1]
10月30日港股通创新药ETF南方（159297）份额增加1.48亿份
Xin Lang Cai Jing·2025-10-31 01:11